Table 4 Comparison of the maximum severity of toxicity between the two treatment groups
| Â | Â | NCI Common Toxicity Criteria Grade | ||||||
|---|---|---|---|---|---|---|---|---|
Toxicity | Treatment group | 0 | 1 | 2 | 3 | 4 | Grade 3/4 (%) | P |
Leucopenia | Regular | 2 | 7 | 8 | 8 | 2 | 10 (37.0%) | 0.079 |
| Â | Split-dose | 19 | 10 | 3 | 6 | 0 | 6 (15.8%) | Â |
Neutropenia | Regular | 8 | 3 | 2 | 7 | 7 | 14 (51.9%) | 0.0005 |
| Â | Split-dose | 26 | 3 | 5 | 4 | 0 | 4 (10.5%) | Â |
Anemia | Regular | 3 | 15 | 8 | 1 | 0 | 1 (3.7%) | > 0.1 |
| Â | Split-dose | 5 | 22 | 9 | 2 | 0 | 2 (5.3%) | Â |
Thrombocytopenia | Regular | 6 | 8 | 8 | 3 | 2 | 5 (18.5%) | > 0.1 |
| Â | Split-dose | 23 | 8 | 4 | 3 | 0 | 3 (7.9%) | Â |
Nausea | Regular | 14 | 11 | 2 | 0 | 0 | 0 | > 0.1 |
| Â | Split-dose | 19 | 14 | 5 | 0 | 0 | 0 | Â |
Vomiting | Regular | 23 | 2 | 2 | 0 | 0 | 0 | > 0.1 |
| Â | Split-dose | 29 | 7 | 2 | 0 | 0 | 0 | Â |
Mucositis | Regular | 22 | 0 | 5 | 0 | 0 | 0 | > 0.1 |
| Â | Split-dose | 29 | 6 | 1 | 2 | 0 | 2 (5.3%) | Â |
Diarrhea | Regular | 18 | 8 | 1 | 0 | 0 | 0 | > 0.1 |
| Â | Split-dose | 29 | 6 | 1 | 2 | 0 | 2 (5.3%) | Â |
Skin rash | Regular | 27 | 0 | 0 | 0 | 0 | 0 | > 0.1 |
| Â | Split-dose | 37 | 1 | 0 | 0 | 0 | 0 | Â |
Fatigue | Regular | 13 | 9 | 3 | 2 | 0 | 2 (7.4%) | > 0.1 |
| Â | Split-dose | 19 | 11 | 7 | 1 | 0 | 1 (2.6%) | Â |
Renal | Regular | 23 | 1 | 0 | 3 | 0 | 3 (11.1%) | 0.067 |
| Â | Split-dose | 37 | 1 | 0 | 0 | 0 | 0 | Â |
Liver dysfunctiona | Regular | 27 | 0 | 0 | 0 | 0 | 0 | > 0.1 |
| Â | Split-dose | 35 | 0 | 3 | 0 | 0 | 0 | Â |
Bleeding | Regular | 20 | 3 | 1 | 3 | 0 | 3 (11.1%) | > 0.1 |
| Â | Split-dose | 35 | 2 | 0 | 1 | 0 | 1 (2.6%) | Â |
Infection | Regular | 23 | 0 | 1 | 0 | 3 | 3 (11.1%) | > 0.1 |
| Â | Split-dose | 29 | 2 | 4 | 3 | 0 | 3 (7.9%) | Â |